Table 1.
Characteristics of the included studies for the use of CHM as an adjunct for chemotherapy in breast cancer patients.
| Study | Number of participants/dropouts | TNM stage | Duration (weeks) | Control group interventions | CHM interventions | Outcome(s) | Jadad scale score |
|---|---|---|---|---|---|---|---|
| Dang and Wang 2010 [22] | 48/0 | I–III | 9 | CTF | Aidi injection | Tumor response, cardiotoxicity, KPS, and chemotoxicity | 3 |
| Barton et al. 2013 [23] | 210/44 | I–IV | 52 | TE/TEC | Ginkgo Biloba | Cognitive dysfunction | 5 |
| Fang 2009 [24] | 60/0 | III/IV | 3 | CTF | Shenqi Wuweizi pill | Tumor response, KPS, and chemotoxicity | 3 |
| Fu and Kou 2007 [25] | 88/0 | IV | 8 | NP | Aidi injection | Tumor response, KPS, chemotoxicity, and median survival | 3 |
| Hong et al. 2014 [26] | 91/7 | II–IV | 18 | TEC | Xihuang pill | Tumor response, KPS, and overall survival | 3 |
| Huang et al. 2003 [27] | 66/0 | II–IV | 4 | CMF | Bazhen decoction | KPS and chemotoxicity | 3 |
| Huang et al. 2007 [28] | 60/0 | IV | 6 | CTF | Jianpi Xiaoji decoction | Tumor response, KPS, and immune system | 3 |
| Huang et al. 2008 [29] | 60/0 | III/IV | 6 | CTF | Shenqi Fuzheng injection | Tumor response, KPS, and chemotoxicity | 3 |
| Huang et al. 2013 [30] | 60/0 | IV | 18–24 | CEF | Huangqi injection | Tumor response, KPS, chemotoxicity, and median survival | 3 |
| Li et al. 2003 [31] | 101/0 | I–III | 6~9 | CMF | Rukang I prescription | Tumor response, KPS, and chemotoxicity | 3 |
| Li and Gong 2006 [32] | 52/0 | I–III | 9 | CEF | Aidi injection | Tumor response and chemotoxicity | 3 |
| Lu 2010 [33] | 60/0 | III/IV | 6 | CAF | Huangqi injection | Tumor response | 3 |
| Lv et al. 2014 [34] | 54/0 | IV | 12–16 | FAC | Yiqi Huoxue Huayu decoction | Tumor response, KPS, chemotoxicity, and immune system | 3 |
| Ni 2006 [35] | 57/0 | IV | 13 | Docetaxel + THP | Gaolisheng injection | Tumor response and chemotoxicity | 3 |
| Pérol et al. 2012 [36] | 430/27 | I–IV | 8–12 | FAC | Cocculine | Chemotherapy-induced emesis | 5 |
| Qi 2010 [37] | 40/0 | II–IV | 6 | TE | Yiqi Yangxue Shugan decoction | Tumor response, KPS, quality of life, and chemotoxicity | 3 |
| Qin 2013 [38] | 78/0 | I–IV | 21 | CAF | Fuzheng Qiqi Jiedu decoction | KPS | 3 |
| Semiglazov et al. 2006 [39] | 352/21 | I–III | 16–24 | CMF | Mistletoe extract | Quality of life | 5 |
| Shen 2007 [40] | 100/0 | IV | 6 | NVB + THP | Aiyishu injection | Tumor response and KPS | 3 |
| Sun et al. 2010 [41] | 86/0 | II–IV | 3 | CAF/AC | Zaofan pill | Chemotoxicity | 3 |
| Wang 2007 [42] | 60/0 | II-III | 9 | CEF | Taohong Siwu decoction | Quality of life and chemotoxicity | 3 |
| Wang 2010 [43] | 40/0 | II–IV | 8 | TE | Yiqijianpi Huayujiedu decoction | Tumor response, quality of life, and chemotoxicity | 3 |
| Wen et al. 2010 [44] | 60/0 | IV | 3 | TA | Fuzheng Xiaoyan prescription | Tumor response, quality of life, chemotoxicity, and immune system | 3 |
| Xiong 2012 [45] | 48/0 | IV | 6 | NVB + CAP | Fuzhengxiaoji decoction | Tumor response and KPS | 3 |
| Yang 2004 [46] | 59/0 | IV | 6 | NVB + THP | Aidi injection | Tumor response, KPS, and immune system | 3 |
| Yang et al. 2008 [47] | 59/4 | III B-IV | 6–8 | NP | Guben Yiliu II decoction | Tumor response and KPS | 3 |
| Yi et al. 2008 [48] | 60/0 | IV | 12 | DOX | Ginkgo Biloba | Cardiotoxicity | 3 |
| Zhang et al. 2010 [49] | 80/0 | I/II/III | 18 | CEF | Huangqi Taohong decoction | Immune system | 3 |
| Zhang et al. 2011 [50] | 45/0 | III-IV | 6 | CTF | Fuzheng Quyu Jiedu prescription | Immune system and quality of life | 3 |
| Zhang and Li 2013 [51] | 96/0 | II-III | 3-4 | CTF | Tiaogan Jianpi prescription | Tumor response | 3 |
| Zhong 2009 [52] | 40/0 | I–IV | 6 | TE | Shugan Tiaoli Chongren decoction | Quality of life, KPS, and chemotoxicity | 3 |
KPS: Karnofsky performance score.